Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02950012 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate OPTI-BIOME™ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population
A Phase 2 study of Bloating, sponsored by BIO-CAT Microbials.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 3
- Study locations
NCT02950012: Completed Phase 2 study of Bloating, sponsored by BIO-CAT Microbials.
NCT02950012 is a Phase 2 study of Bloating that has completed, run by BIO-CAT Microbials. The registered enrollment target is 100 participants, above the 83-participant average among 5 other Bloating trials with a reported enrollment target (20% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02950012, a Phase 2 study of Bloating, has completed, sponsored by BIO-CAT Microbials.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to investigate the effects of OPTI-BIOME™ (Bacillus subtilis MB40), a probiotic supplement, on bloating, gas and abdominal discomfort symptoms in otherwise healthy adults.
Primary Outcome
Discomfort, Gas and Bloating questionnaire
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT OPTI-BIOME™ Bacillus subtilis MB40
Study Locations (3)
California
- KGK Clinical Trials Center - Foothill Ranch
Florida
- KGK Clinical Trials Center - Orlando
Ontario
- KGK Synergize Inc. - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-10 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
What the finished NCT02950012 record still lists
NCT02950012 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 83-participant average among 5 other Bloating trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Bloating appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02950012 reports a single indexed study location in California, Florida, Ontario.
Frequently Asked Questions
What is clinical trial NCT02950012 about?
NCT02950012 is a clinical study titled "A Study to Evaluate OPTI-BIOME™ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population". The purpose of this study is to investigate the effects of OPTI-BIOME™ (Bacillus subtilis MB40), a probiotic supplement, on bloating, gas and abdominal discomfort symptoms in otherwise healthy adults.
What is the current status of trial NCT02950012?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2016-10. Estimated completion is 2017-02.
What conditions does trial NCT02950012 study?
This clinical trial studies the following conditions: Bloating.
What interventions are being tested in trial NCT02950012?
The interventions under investigation include: Placebo (OTHER), OPTI-BIOME™ Bacillus subtilis MB40 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02950012?
This trial is sponsored by BIO-CAT Microbials, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02950012 being conducted?
This trial has 3 study locations across California, Florida, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bloating
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Diaphragmatic Breathing for the Treatment of Bloating and Distension
RECRUITING · NA
-
Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women
RECRUITING · NA
-
Study to Evaluate a Probiotic in Healthy Subjects With a History of Abdominal Discomfort and Bloating
COMPLETED · NA
-
Treatment of Symptomatic Bloating Using a Novel Hypnotherapy Protocol
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia